Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 110, Issue 1, Pages 31-39
Publisher
Oxford University Press (OUP)
Online
2017-06-15
DOI
10.1093/jnci/djx141
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer
- (2017) Husam Abdel-Qadir et al. JAMA Cardiology
- Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials
- (2016) Lisa Rydén et al. BREAST
- Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies
- (2016) A. Srikanthan et al. CANCER TREATMENT REVIEWS
- The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer
- (2016) Husam Abdel-Qadir et al. EUROPEAN JOURNAL OF CANCER
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- (2016) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neither fixed nor random: weighted least squares meta-regression
- (2016) T. D. Stanley et al. Research Synthesis Methods
- Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?
- (2015) Shaun Treweek et al. EUROPEAN JOURNAL OF CANCER
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- (2015) LANCET
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
- (2011) D.B.Y. Fontein et al. EJSO
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- (2011) Cornelis JH van de Velde et al. LANCET
- Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes
- (2009) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started